Globenewswire·2025-10-27 12:00Core Insights - Artelo Biosciences, Inc. has appointed Mark Spring as Chief Financial Officer effective November 1, 2025, enhancing the company's financial leadership as it progresses its clinical pipeline and corporate growth initiatives [1][3] Company Overview - Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions including cancer, pain, and dermatological issues [4] - The company is advancing a portfolio of product candidates aimed at addressing significant unmet medical needs across multiple diseases [4] Leadership Experience - Mark Spring brings 30 years of experience in life sciences, having held financial leadership roles in both private and public companies, including significant experience in mergers and acquisitions [2][3] - His previous roles include interim CFO for LENZ Therapeutics and co-founder and CFO of Secura Bio, among others [2] Strategic Impact - Since joining as a financial consultant in December 2024, Mark Spring has strengthened Artelo's financial operations and supported the execution of its capital strategy [3] - His leadership is expected to be crucial in advancing the company's product candidates and enhancing shareholder value [3]